The QUAZAR AML-001 maintenance trial: Results of a phase III international, randomized, double-blind, placebo-controlled study of oral CC-486 in patients with Acute Myeloid Leukemia (AML) in first remission
Dohner, H; Wei, AH; Pocock, C; Montesinos, P; Dombret, H; Ravandi, F; Sayar, H; Jang, JH; Porkka, K; Selleslag, D; Sandhu, I; Turgut, M; Giai, V; Ofran, Y; Cakar, MK; de Sousa, AB; Rybka, J; Frairia, C; Borin, L; Beltrami, G; Cermak, J; Pfeilstocker, M; Thol, F; Feldmann, G; Ossenkoppele, GJ; La Torre, I; Skikne, B; Kumar, K; Dong, Q; Beach, CL; Roboz, GJ
ONCOLOGY RESEARCH AND TREATMENT, 2020; 43 (SUPPL 4): 38
